Compare Cytokinetics Inc (CYTK) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Lamb Weston Holdings Inc — how do they compare? Cytokinetics Inc trades at $76.64 (market cap $10.63B), while Lamb Weston Holdings Inc trades at $52.71 (market cap $7.23B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Lamb Weston Holdings Inc pays a 2.89% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | LW | |
|---|---|---|
Market Cap | $10.63B | $7.23B |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $66.57 |
52-Week Low | $34.31 | $38.48 |
Enterprise Value | $10.74B | $11.10B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Lamb Weston (LW) trades at $51.81, down 0.88% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 16.28% ROE and a 4.39% net margin, supported by positive cash flow from operations of $868.3M in 2025. Recent news highlights Q4 2026 results exceeding expectations and a declared $0.38 dividend.
Outlook remains positive with a consensus price target of $53.86, though risks include margin pressure from cost inflation and international headwinds. The stock offers a solid dividend yield and growth potential from operational improvements, but investors should monitor debt levels and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
